ASCO

Biotech Matthew Herper

STAT Plus: With the right molecular signal, a cancer drug works in every patient

Pharma Adam Feuerstein

STAT Plus: Roche’s TIGIT troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target

Biotech Angus Chen

STAT Plus: Promising results reported for new generation of CAR-T immunotherapy for myeloma

Biotech Matthew Herper

STAT Plus: Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients

Biotech Adam Feuerstein

STAT Plus: With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment

Biotech Adam Feuerstein

Virtual Event: The ASCO Recap, Live!

Biotech Adam Feuerstein

STAT Plus: Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?

Pharma Adam Feuerstein

STAT Plus: For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer

Biotech Adam Feuerstein

STAT Plus: Allogene’s blood cancer data show durability of off-the-shelf CAR-T cells

Pharma Adam Feuerstein

STAT Plus: With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease

Biotech Adam Feuerstein

STAT Plus: Merus drug shows potential as treatment for rare type of pancreatic cancer

Biotech Adam Feuerstein

Virtual Event: The ASCO Recap, Live!

First Opinion Maura McCarthy

Early diagnosis, not cancer drug breakthroughs, is the best way to fix the global scourge of breast cancer

Biotech Adam Feuerstein

STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows

Biotech Adam Feuerstein

STAT Plus: AstraZeneca study results could change treatment for certain early-stage lung cancer patients

Biotech Adam Feuerstein

STAT Plus: Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study

Biotech Adam Feuerstein

STAT Plus: Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show

The Readout LOUD Adam Feuerstein and Matthew Herper

Listen: A special episode from the halls of the ASCO meeting

Biotech Adam Feuerstein and Matthew Herper

STAT Plus: What you missed at ASCO? A lot, as cancer research hastens on

Biotech Adam Feuerstein

STAT Plus: At ASCO, targeted lung cancer drugs shrink tumors caused by rare genetic mutations

Biotech Matthew Herper

STAT Plus: Tempus, a well-funded company run by a Groupon billionaire, wants to get patients into clinical trials

Biotech Adam Feuerstein

STAT Plus: Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients

Health Matthew Herper

The Affordable Care Act erased a racial disparity in cancer care, a new study says

Pharma Matthew Herper

STAT Plus: Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs

Biotech Matthew Herper

STAT Plus: Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t